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Androgens [testosterone and dihydrotestosterone (DHT)] act via the androgen receptor (AR) through classical genomic actions that involve DNA binding and transcriptional regulation of target genes (7) , although the target genes in fat are mostly unknown. In addition, nongenomic actions that are characterized by rapid second messenger phosphorylation without DNA binding have been identified in vitro (22) . Supraphysiological doses of testosterone cause rapid coronary vasodilation in vivo (55, 60) , but it is not known whether nongenomic signaling plays a physiological role in fat metabolism. Testosterone can also be converted to estradiol via aromatase, which is highly expressed in adipose tissue in humans (51) and in mice (61) . Estrogens regulate lipid metabolism in males, demonstrated by increased adiposity in both male and female aromatase knockout mice (25) , and in estrogen receptor (ER)␣ knockout males (43) . Therefore, the contribution of androgen action mediated by AR in fat mass and metabolism remains unclear, with limited and conflicting data to date (31, 45, 49, 58) .
Two AR knockout (ARKO) models have been generated with complete AR deletion that have a late-onset obese phenotype (31, 49) . Chang et al., who generated an exon 2-deleted AR-null model, showed that AR deletion causes increased leptin levels and leptin resistance, leading to obesity and insulin resistance (31) . In contrast, the Kato group, who generated an exon 1-deleted AR-null model, showed no effect of AR deletion on insulin sensitivity, but instead reduced spontaneous activity and oxygen consumption resulting in obesity (14) . They also suggested that the androgen-AR system inhibits secretion of the insulin sensitizer adiponectin from adipose tissue (14) . A third AR-null model, also with exon 2 deleted, was developed by Verhoeven and colleagues, but in contrast to the other models, these mice do not develop adiposity or obesity (45) . It is not clear why differences in adiposity and insulin resistance arise between the different models, since all have complete absence of AR protein [Supplemental Table S1 (supplemental materials are found with the online version of the paper at the Journal website)]. Furthermore, it remains unknown whether nongenomic AR pathways contribute to these changes.
Our global DNA binding-dependent (DBD)-ARKO mouse model has an in-frame deletion of exon 3 of the AR gene, which encodes the second zinc finger of the DBD (41) . DBD-ARKO males have a sex-reversed XY female phenotype, with small intra-abdominal testes and no prostate or seminal vesicles (41) . Our model has deletion of AR DNA binding-dependent actions, but potential nongenomic actions are retained because AR protein is expressed normally. We hypothesize that androgens act directly via the DNA binding-dependent actions of the AR to regulate genes controlling fat mass and metabolism. The aim of this study was to determine the effect of global DBD-AR knockout on metabolic phenotype and gene expression.
MATERIALS AND METHODS
Mice. Global DBD-ARKO mice were generated as previously described (35) , back-crossed onto a C57BL/6 background for more than eight generations. Wild-type (WT) male littermates were used as controls. All mice were housed on a 12:12-h light-dark cycle, with laboratory chow and water available ad libitum, except as otherwise described. For high-fat diet studies, mice aged 12 wk were randomized into two diet groups (n ϭ 11-12/genotype) of chow (9% fat, 3.701 kcal/g; Barastoc, Victoria, Australia) or high-fat diet (60% fat, 6.686 kcal/g; Glen Forrest Stockfeeders, Western Australia, Australia; Supplemental Table S2 ). Mice were maintained on these diets for 12 wk. All studies were performed with the approval of the Austin Health Animal Ethics Committee.
Voluntary physical activity, food intake, energy expenditure, and substrate oxidation rates. Voluntary physical activity, using computerlinked running wheels (Lafayette Instruments), was measured at 12 wk (n ϭ 11-13/genotype), 24 wk (n ϭ 11-14/genotype), and 52 wk (n ϭ 3-6/genotype), with measurements taken daily for 4 days, as previously described (16) . Food intake and body weight were measured weekly from 4 -24 wk of age for the chow diet (n ϭ 7-13/ genotype) and from 12 to 24 wk of age for the high-fat diet (n ϭ 8/genotype). Resting energy expenditure (REE) and substrate oxidation rates (fat and glucose) as well as respiratory quotients were measured at 12 wk (n ϭ 12/genotype), 24 wk (n ϭ 11/genotype), and 52 wk (n ϭ 3-4/genotype) using the Oxymax open circuit indirect calorimetry system (Columbus Instruments), as described (16) . Measurements were made in a chamber for 1 h in a nonfasted, resting state during the light cycle.
Insulin tolerance tests. Intraperitoneal (ip) insulin tolerance tests were performed at 12 wk (n ϭ 8 -10/genotype) and 24 wk (n ϭ 10/genotype). Ten minutes following injection with pentabarbitol sodium (100 mg/kg body wt ip), a basal blood glucose reading (0 min) was taken via tail snipping and read on a handheld glucometer (Optium, Abbott Laboratories). Mice were then injected with a bolus of insulin (0.75 U/kg body wt ip; Actrapid, Novo Nordisk), and blood glucose readings were taken at 15, 30, 45, and 60 min postinjection.
Blood and tissue collection. Blood and tissue were collected from WT and DBD-ARKO male littermates aged 9 wk (n Ն 17/genotype), 12 wk (n Ն 17/genotype), 24 wk (n Ն 11/genotype), and 52 wk (n Ն 6/genotype). Mice were fasted for 6 h prior to euthanasia and collection of blood and tissues. Blood was collected by cardiac puncture following ip injection of pentabarbitol sodium. After being clotted on ice, serum was separated by centrifugation, 2 ϫ 8min at 4,500 rpm, and stored at Ϫ20°C prior to analysis. Following blood collection, fat pads [subcutaneous, retroperitoneal (representative of visceral fat), gonadal, and intrascapular brown adipose tissue (BAT)], heart, and gastrocnemius muscle were dissected, weighed, and snap-frozen. Wet weight of tissues was determined to an accuracy of 0.1 mg from the mean of the bilateral tissues. Fat mass was not corrected for body mass, because body mass is androgen dependent (2); therefore, expressing fat mass relative to body mass could potentially mask or exaggerate androgen-dependent differences in tissue mass (2) .
Serum assays. Fed glucose and insulin levels were measured at 12 wk (n ϭ 11-14/genotype), and fasted glucose and insulin levels were measured at 24 wk (n ϭ 10 -13/genotype) and 52 wk (n ϭ 7-8/ genotype), using a GM7 Analox glucose analyzer (Helena Laboratories, Victoria, Australia), and insulin RIA (Linco Research Immunoassay). Fasted serum cholesterol and triglycerides were measured at 12 wk (n ϭ 10 -11/genotype), 24 wk (n ϭ 8 -12/genotype), and 52 wk (n ϭ 7-8/genotype) on an autoanalyzer by Austin Pathology (Austin Health, Victoria, Australia). Fasted adiponectin and leptin levels were measured at 12 wk (n ϭ 8 -10/genotype), 24 wk (n ϭ 8 -12/genotype), and 52 wk (n ϭ 7-8/genotype) by enzyme immunoassay (Quantikine Immunoassay). Serum testosterone levels were measured at 12 wk (n ϭ 12-20/genotype) and 52 wk (n ϭ 2-3/genotype), using an enzyme immunoassay (R&D Systems), following organic extraction of the serum, as previously described (34) .
Fat and liver histology. Subcutaneous fat from 12-wk and liver from 12-and 24-wk mice were fixed overnight in 10% neutral buffered formalin (n ϭ 2-3/genotype). Following paraffin processing and embedding, 10-m sections were stained with hematoxylin and eosin (H&E). Images of fat sections were captured on an Olympus BH2-RFCA microscope, and adipocyte area was determined using ImageJ software (v. 1.42q). Cell size was dichotomized into five cell area categories (0 -500, 500 -1,000, 1,000 -1,500, 1,500 -2,000, and Ͼ2,000 m 2 ), and the frequency of each category was calculated from the total number of cells. Liver sections were analyzed on a Nikon Eclipse E600 microscope by the School of Medical Sciences, RMIT University (Victoria, Australia).
Molecular analyses. Total RNA was isolated from subcutaneous fat using the RNeasy Lipid Midi Kit (Qiagen) and from skeletal muscle (gastrocnemius) using standard methodologies. RNA was DNase treated and cDNA synthesized as previously described (35) . Microarray analysis was performed by the Australian Genome Research Facility using the Affymetrix system (Millennium Sciences, Victoria, Australia). RNA (1.5 g) from WT and DBD-ARKO male gastrocnemius muscle (n ϭ 2/genotype) and subcutaneous fat (n ϭ 3/genotype) were analyzed using the Affymetrix mouse genome 430 2.0 array. Androgen-responsive genes were identified as previously described (35) . Ingenuity pathway analysis was used to identify pathways, processes, and functions that were overrepresented in the androgen-responsive gene set (www.ingenuity.com). Quantitative real-time PCR (qPCR) was performed with 12-wk WT and DBD-ARKO male gastrocnemius muscle and subcutaneous fat (n ϭ 10 -15/genotype) as previously described (35) (Supplemental Table S3 ).
Protein from 9-wk subcutaneous fat was isolated in radioimmunoprecipitation assay (RIPA) buffer with complete protease inhibitor (Roche, Baden-Württemberg, Germany; n ϭ 4 -5/genotype). Western analysis was performed using 10% SDS-PAGE, 30 mg protein/lane, and polyvinylidene difluoride membrane (PVDF). Phosphorylated ERK1/2, CREB, and Akt were detected using anti-phosphorylated ERK1/2 (Thr 202 and Tyr 204 ), anti-phosphorylated-CREB (Ser 133 ), and anti-phosphorylated-Akt (Ser 473 ) antibodies (Cell Signaling Technology; 1 in 1,000 in 5% BSA-TBS-T), overnight at 4°C. Signal was detected with Western Lightning Plus chemiluminescent reagent (PerkinElmer Life Sciences) and the Fujifilm LAS-3000 detection system for densitometric quantitation. The same membranes were probed with anti-ERK1/2, -CREB, and -Akt antibodies (Cell Signaling Technology), and the ratios of phosphorylated to total ERK1/2, CREB, and Akt were calculated and expressed relative to control.
Statistical analysis. Data are expressed as means Ϯ SE. For comparison of group means, data were analyzed by two-tailed unpaired Student's t-test using Levene's test for homogeneity (SPSS Statistics 17.0). Fat histology data were analyzed using 2 analysis. Gene ontology (GO) distributions were analyzed by 2 analysis using the Ingenuity Pathway Analysis online tool.
RESULTS

Body mass and tissue mass.
To identify the metabolic actions of androgens mediated via DNA binding-dependent AR signaling, we characterized DBD-ARKO males fed a chow diet compared with their WT male littermates. At 9 -24 wk, total body mass was decreased by 12-16% in DBD-ARKO males compared with WT (Fig. 1A) . At 52 wk, there was no difference in total body mass between WT and DBD-ARKO males.
Subcutaneous fat mass was increased by 21% in DBD-ARKO males compared with WT at 9 wk, by 75% at 12 wk, and by 188% at 52 wk (Fig. 2, A-D) . Visceral fat mass was not different between DBD-ARKO males and WT males at 9 or 24 wk but was increased by 36% in DBD-ARKO males at 12 wk and by 72% at 52 wk (Fig. 2, E-H) . In contrast, gonadal fat mass was decreased by 38 -58% in DBD-ARKO males compared with WT males at 9, 12, and 24 wk of age but did not differ at 52 wk (data not shown). BAT mass was measured at 24 and 52 wk and was decreased by 26% in DBD-ARKO males at 24 wk but did not differ at 52 wk (Fig. 2, I and J). Gastrocnemius muscle mass was decreased in DBD-ARKO males at 9, 12, and 24 wk of age (data not shown), confirming our previous findings (35), although no difference was observed at 52 wk.
To potentially maximize the phenotypic differences between DBD-ARKO and WT males, 12-wk-old mice were placed on a high-fat diet for 12 wk. After high-fat feeding, there was no difference in total body mass in WT males compared with the chow diet (Fig. 1B) . The mean total body mass value of DBD-ARKO males was 9% higher on the high-fat diet than on the chow diet, but this did not reach statistical significance (P ϭ 0.077). However, after the high-fat diet, total body mass in DBD-ARKO males was the same as in WT males (Fig. 1B) .
Despite the high-fat diet not increasing total body mass, both WT and DBD-ARKO mice had increased adiposity compared with the chow diet. Subcutaneous fat mass was increased by 62% in WT compared with the chow diet and by 71% in DBD-ARKO males (Fig. 2C) . However, following high-fat feeding, subcutaneous fat mass was still 66% higher in DBD-ARKO males than in WT (Fig. 2C ). Visceral fat mass was also increased in both WT (59%) and DBD-ARKO males (52%) on the high-fat compared with the chow diet ( Fig. 2G ), but there was no difference in visceral fat mass between WT and DBD-ARKO males on the high-fat diet. Gonadal fat mass was also increased in both WT and DBD-ARKO males on the high-fat diet and was still lower in DBD-ARKO than in WT males (data not shown). BAT mass was decreased in WT males (33%) following the high-fat diet but did not change in DBD-ARKO males (Fig. 2I) .
Voluntary physical activity, food intake, energy expenditure, and substrate oxidation rates. To determine the effect of DBD-ARKO on physical activity, voluntary activity was measured. Voluntary activity was decreased by 70% at 12 wk in DBD-ARKO males compared with WT males (Fig. 3A) and by 76% at 24 wk (Fig. 3B) . At 52 wk, the mean value for voluntary activity was 80% lower in DBD-ARKO males compared with WT; however, this was not significantly different (P ϭ 0.117) (Fig. 3C ). Both WT and DBD-ARKO males had increased voluntary activity following high-fat feeding but was still 49% lower in DBD-ARKO males compared with WT males on the high-fat diet (Fig. 3B ). Absolute food intake was lower in DBD-ARKO males than in WT on the chow diet in weight (g/wk) at 4 -12 wk (WT: 29.1 Ϯ 1.0 vs. DBD-ARKO: 24.7 Ϯ 0.9 g/wk, mean Ϯ SE, P Ͻ 0.05) and from 12-24 wk (WT: 29.7 Ϯ 0.6 vs. DBD-ARKO: 25.9 Ϯ 0.8 g/wk, P Ͻ 0.001), as well as in energy intake (kcal/wk) ( Fig. 3D and data not shown). Both WT and DBD-ARKO males had reduced absolute food intake in weight on the high-fat diet compared with the chow diet ( Fig. 3D and data not shown), but there was no difference in food intake between WT and DBD-ARKO males on the high-fat diet (WT: 14.4 Ϯ 0.5 vs. DBD-ARKO: 13.6 Ϯ 0.7 g/wk, P ϭ 0.42).
At 12 wk, there was no difference in REE, fat oxidation, or glucose oxidation rates between WT and DBD-ARKO males (Fig. 4, A and B) . At 24 wk, REE was increased by 11% in DBD-ARKO males compared with WT ( Fig. 4C ), but there was no difference in fat oxidation or glucose oxidation rates ( Fig. 4D) . At 52 wk, there were no differences in any of these parameters (Fig. 4 , E and F). High-fat feeding resulted in no change in REE in WT or DBD-ARKO males (Fig. 4C) , and there was also no difference in REE between WT and DBD-ARKO males within the high-fat diet group. Fat oxidation rate was increased in both WT and DBD-ARKO males on the high-fat diet compared with the chow diet (Fig. 4D ) but did not differ between WT and DBD-ARKO males on the high-fat diet. Conversely, glucose oxidation rate was decreased in both WT and DBD-ARKO males on the high-fat diet (Fig. 4D ), but there was no difference between WT and DBD-ARKO males on the high-fat diet. Multiple regression analysis could not be performed, as total fat mass and total lean body mass were not measured. There was no significant difference in respiratory quotient between WT and DBD-ARKO in any of the groups (Table 1) .
Glucose, insulin, and lipid homeostasis. To determine whether DBD-ARKO affected insulin or altered lipid homeostasis, glucose, insulin, cholesterol, and triglyceride levels were measured. DBD-ARKO males had normal serum glucose and insulin levels at 12, 24, and 52 wk of age (Fig. 5, A-F) . Insulin tolerance tests also showed no difference in glucose levels between WT and DBD-ARKO males at 12 or 24 wk (Fig. 5, G  and H) . There was no effect of high-fat feeding on glucose levels in WT males (Fig. 5B ), but mean insulin levels, although not significant, were 62% higher in WT males on the high-fat compared with chow diet (P ϭ 0.063; Fig. 5E ). There were no differences in glucose or insulin levels in DBD-ARKO males between the two diet groups or between WT and DBD-ARKO males on the high-fat diet. Serum cholesterol and triglyceride levels were normal in DBD-ARKO males at 12, 24, and 52 wk (Fig. 5, I-N) . High-fat feeding increased cholesterol levels in both WT and DBD-ARKO males (36 and 26%, respectively; Fig. 5K ), but there was no significant difference between WT and DBD-ARKO males on the high-fat diet (P ϭ 0.072). There was no effect of high-fat feeding on serum triglyceride levels in either WT or DBD-ARKO males (Fig. 5L ). The mean serum triglyceride level was lower in DBD-ARKO males compared with WT on the high-fat diet, but this did not reach statistical significance (P ϭ 0.056).
Leptin and adiponectin homeostasis. Serum leptin and adiponectin levels were measured at 12, 24, and 52 wk. Serum leptin levels were 518% higher in DBD-ARKO males compared with WT at 12 wk and 491% higher at 52 wk, with a trend for increased levels at 24 wk (P ϭ 0.055; Fig. 6, A-C) . Similarly, serum adiponectin levels were 86 -153% higher in DBD-ARKO males compared with WT males at all time points (Fig. 6, D-F) . High-fat feeding caused leptin to increase by 168% in WT males but did not alter leptin levels in DBD-ARKO males (Fig. 6B) , resulting in no difference in leptin between WT and DBD-ARKO on the high-fat diet. High-fat feeding did not alter adiponectin levels in WT but caused a 22% decrease in DBD-ARKO males (Fig. 6E) . However, adiponectin levels were still higher in DBD-ARKO males than WT males on the high-fat diet (Fig. 6E) .
Testosterone levels. Serum testosterone levels were measured at 12 and 52 wk. At 12 wk, levels were 78% lower in DBD-ARKO males than in WT males (WT: 14.0 Ϯ 4.6 vs. DBD-ARKO: 3.1 Ϯ 0.3 nmol/l, P Ͻ 0.05) but were not different between genotypes at 52 wk (WT: 6.3 Ϯ 4.0 vs. DBD-ARKO: 1.4 Ϯ 1.0 nmol/l). Power calculations show that, given the small sample size of the 52 wk group, only a difference of Ն95% could be detected. Fat and liver histology. Adipocyte area from subcutaneous fat sections was measured at 12 wk (Fig. 7, A and B) . There was a significant shift in distribution of cell area in the DBD-ARKO males, with more, larger cells (Fig. 7C) . Liver from 12-and 24-wk WT and DBD-ARKO males was examined for the presence of hepatic steatosis. There was no accumulation of fat droplets in liver sections, although sections from both WT and DBD-ARKO liver showed some cellular degradation (data not shown).
Molecular analyses. Microarray analysis was performed on RNA from gastrocnemius muscle (http://www.ebi.ac.uk/ arrayexpress/files/E-MTAB-597) and subcutaneous fat (http:// www.ebi.ac.uk/arrayexpress/files/E-MTAB-598) in DBD-ARKO and WT male mice. Ninety-six genes showed Ն1.6-fold altered expression on microarray analysis in DBD-ARKO muscle (35) , and gene ontology analysis identified metabolic processes, including quantity of fatty acid and lipid, lipid oxidation, fatty acid transport, oxidation, uptake, and synthesis and clearance of triacylglycerol (Table 2 ). Nine hundred forty-nine genes showed Ն1.6-fold altered expression in DBD-ARKO fat, including genes involved in quantity of fatty acid and triacylglycerol, fatty acid transport, lipid production, synthesis, accumulation, clearance, storage, and uptake (Table 3 and  Supplemental Tables S4 and S5) . qPCR was performed on 10 metabolic genes to confirm microarray results in muscle and fat. In DBD-ARKO muscle, Aebp1 mRNA expression was increased 2.8-fold, Cbr2 was decreased 6.7-fold, Ucp3 was decreased 1.8-fold, and Vldlr was decreased 2.7-fold compared with WT (Fig. 8A) . In DBD-ARKO fat, Aebp1 mRNA expression was decreased 1.9-fold, Ucp3 was increased 4.5-fold, and Ppar␣ was increased 5-fold in DBD-ARKO males compared with WT (Fig. 8B) . Western analysis of second messengers was performed in subcutaneous fat. Phosphorylated CREB relative to total CREB was significantly increased in DBD-ARKO males compared with WT (Fig. 8, C and D) , but there was no difference in the degree of ERK1/2 or Akt phosphorylation.
DISCUSSION
We have used our DBD-ARKO model, which has an inframe deletion of exon 3 of the AR but normal AR protein expression levels (Ref. 41 and data not shown) to examine androgen actions on fat mass and metabolism. We show that deletion of the DNA binding-dependent actions of the AR in males causes, either directly or indirectly, increased fat mass and decreased voluntary physical activity but normal insulin sensitivity. Global DBD-ARKO mice have deletion of the AR DNA binding domain in all tissues at all times; therefore, this phenotype is likely to arise due to loss of DNA bindingdependent AR actions during development as well as in adulthood.
Clinical studies using androgen supplementation or withdrawal in men suggest that androgen levels show an inverse relationship with fat mass, demonstrating that androgens can regulate fat mass in adulthood (3, 38, 52) . In contrast, our study using DBD-ARKO male mice has identified the net actions of androgens acting via the DNA binding-dependent actions of the AR on energy metabolism throughout development. Similar to XY individuals with complete androgen insensitivity syndrome (CAIS) (11, 37) , our DBD-ARKO male mice, on a homogeneous C57BL/6 background, have a lower total body mass than WT males. However, despite being smaller, DBD-ARKO male mice have increased adiposity. In contrast to patients with CAIS, who have elevated testosterone and estradiol levels due to loss of feedback regulation, DBD-ARKO mice have reduced serum testosterone due to increased temperature of intra-abdominal testes and decreased steroidogenesis (42) and because murine 17␣-hydroxylase gene is partially androgen dependent (39) . Therefore, the metabolic phenotype is highly likely to be caused by loss of AR signaling rather than hyperestrogenemia. Although estradiol levels could not be measured due to limited serum; given that testosterone is not elevated, we expect that there would not be elevated estradiol. The finding of reduced body mass but increased adiposity differs from all three published AR-null ARKO models. Two AR-null ARKO models have an obese phenotype of increased total body mass (14, 31, 49, 58) . In the Kato model (exon 1 deletion, mixed C57BL/6 and CD-1 background), total body mass is increased from 10 wk, and subcutaneous and visceral fat mass are increased by 30 wk (14, 49) ; in the Chang model (exon 2 deletion, mixed C57BL/6 and 129SEVE background), total body mass and visceral fat mass are increased by 22 wk (31, 58) . Muscle mass is reported to be unchanged in both these AR-null models (14, 31), unlike the decreased muscle mass in our DBD-ARKO model (35) . In contrast, the Verhoeven ARnull model (exon 2 deletion, homogeneous C57BL/6 background) has a lower lean body mass but no change in fat mass between 5 and 16 wk, as determined by DEXA (44) . Differences in the phenotype observed in our model compared with these other models that have late-onset obesity may arise through non-DNA binding-dependent actions of the AR or may be due to differences in the genetic background (31, 48) . Genetic background affects numerous trait characteristics, from body composition, bone mineral density, lipid levels, glucose levels, and hormone levels to activity (1, 30, 53) . Of the three ARKO models already described, our model can be directly compared with the Verhoeven model (44), as both are on a C57BL/6 background. The lack of adiposity phenotype in the Verhoeven model could be due to the relative insensitivity of DEXA analysis to detect changes in specific fat depots vs. direct measurements of fat pad weight. Alternatively, the increased fat mass in our DBD-ARKO males compared with the AR-null Verhoeven model raises the possibility that DNA binding-dependent and nongenomic AR pathways have opposing actions in fat, so that deletion of the DNA binding- dependent pathway alone results in adiposity, whereas deletion of both pathways has no effect. In men, low androgen levels are associated with an increase in central adiposity (6) . The fact that both subcutaneous and visceral fat mass are increased in DBD-ARKO males demonstrates that both types of fat depots are androgen responsive. In contrast to other fat pads, gonadal fat mass is decreased in our DBD-ARKO males, which, we hypothesize, is due to the lack of development of the internal reproductive tract. Analysis of subcutaneous adipocyte area demonstrates that DBD-ARKO males have more larger cells, suggesting that the increased fat mass is caused by increased fat accumulation per cell. The phenotype of our DBD-ARKO model is consistent with studies that suggest that androgen action on fat is direct rather than a secondary consequence of AR deletion throughout life. Testosterone replacement decreases fat mass in hypogonadal and normal men (5, 8, 28) , and orchidectomy increases fat mass in rodents, which is reversed following androgen treatment (18) , showing androgen regulation of fat mass in adulthood. Furthermore, androgens inhibit adipogenesis in vitro (21), demonstrating direct actions on fat cells.
A major cause of the increased fat mass in DBD-ARKO males is also likely to be due to their decreased voluntary physical activity. There are two different measures of physical activity in mice, voluntary activity, measured on running wheels, and spontaneous activity, measured with infrared sensors in cages to record ambulatory locomotor movement. The estrogen-deficient aromatase knockout mouse model has increased abdominal fat and shows decreased spontaneous activity (25) but increased voluntary activity (23) , demonstrating that these two types of activity can be regulated in an opposing manner. The decreased voluntary activity in our DBD-ARKO males is similar to that of the Verhoeven group's AR-null model (44) , supporting the hypothesis that androgens act through the AR to increase voluntary activity. We have recently shown that male mice with muscle-specific AR deletion have a mild reduction in muscle mass but normal voluntary activity levels (unpublished data). This suggests that the decreased activity in global DBD-ARKO males is due to the AR in tissues other than muscle and that the reduction in gastrocnemius mass in DBD-ARKO males is not solely a secondary consequence of the reduced activity of the mice, although this could be a contributing factor. A central nervous system (CNS)-specific-ARKO model (exon 2 deletion, mixed C57BL/6 and 129SvEv background) shows increased spontaneous ambulatory activity, but voluntary activity was not measured, demonstrating that spontaneous activity is downregulated by androgens, and this occurs centrally (47) . The fact that androgens increase voluntary activity but decrease spontaneous activity in ARKO males is similar to the opposing estrogen activities in the aromatase knockout mice. However, the Kato group reported a conflicting finding of decreased spontaneous activity in their exon 1-deleted AR-null male mice (mixed C57BL/6 and CD-1 background) (14) . This could either be due to the effect of mixed genetic background or may indicate opposing regulation of spontaneous activity in the CNS vs. other target tissues. Our data demonstrate that DBD-AR pathways regulate voluntary physical activity, and while this is not due to actions in muscle, the target tissue mediating this action remains to be determined.
The increased adiposity observed in our DBD-ARKO model occurred despite a decrease in absolute food intake. Ophoff et al. reported a similar absolute food intake reduction in sedentary ARKO males (44); however, both the Kato and Chang groups reported no change in food intake in their respective ARKO models (31, 49) . Therefore, our data demonstrate that DBD-AR actions regulate food intake. The decrease in food intake in DBD-ARKO males may be a secondary consequence of their decreased activity or decreased lean body mass. In addition, it is possible that there is direct androgen regulation of food intake. Androgen levels are negatively associated with leptin levels in men (33) , and androgen treatment lowers leptin levels in hypogonadal men (50) and decreases both leptin and adiponectin levels in diabetic men (26) . We found that serum leptin levels are elevated in DBD-ARKO males and are therefore associated with increased fat mass, consistent with these clinical studies. This finding is also consistent with the decreased food intake in the DBD-ARKO males and suggests that although the mice have hyperleptinemia they are not leptin resistant. In contrast, the Chang AR-null model shows increased leptin levels despite no change in food intake, and following leptin treatment in aging mice there is no weight loss, suggesting that AR-null mice are leptin resistant (31) .
The increased fat mass in DBD-ARKO males was not caused by decreased REE, which was increased at 24 wk but normal at 12 and 52 wk. The observation of increased REE in our DBD-ARKO males, which also have decreased muscle mass compared with WT males, suggests that the androgenic control of REE is not secondary to changes in lean body mass. In contrast to our study, the Kato group found decreased oxygen consumption at 22 wk in AR-null males (14) . BAT mass in our model was decreased at 24 wk but was unchanged at 52 wk. This study was limited by a lack of further BAT analysis, and therefore the reasons for this finding are unclear.
Obesity is associated with insulin resistance and type 2 diabetes, and diabetic men commonly have low testosterone levels, but it is not known whether obesity causes low testosterone or decreased androgen signaling causes insulin resistance (20) . Glucose and insulin levels were normal in our DBD-ARKO males, and insulin sensitivity, assessed by insulin tolerance tests, was normal in our DBD-ARKO model. Therefore, despite the increased subcutaneous and visceral fat mass in DBD-ARKO males, insulin resistance did not develop. Kato et al. also observed no difference in insulin sensitivity in their AR-null model and, similar to our group, found elevated adiponectin levels (14) . However, Lin et al. reported that their AR-null male mice showed elevated serum glucose and insulin resistance, attributing this to increased leptin levels and leptin resistance (31) . Our data demonstrate that, even when on the diabetes-susceptible C57BL/6 background (54) and on a highfat diet, deletion of the DNA binding-dependent actions of the AR does not cause insulin resistance despite causing adiposity. This suggests that either the increase in circulating adiponectin is contributing to the normal insulin sensitivity or the DBD-AR pathway does not play a major role in insulin sensitization. The conflicting data from the clinical studies investigating the effects of testosterone therapy on insulin resistance in men with type 2 diabetes (19, 27, 40) suggest that further studies are required to clarify the relationship between androgens, the AR, and insulin sensitivity.
Deletion of the DNA binding-dependent actions of the AR does not make DBD-ARKO males more susceptible to a high-fat diet than WT mice. When DBD-ARKO are compared with WT within the high-fat diet group, subcutaneous fat mass and adiponectin levels are increased, whereas gonadal fat mass and voluntary activity levels are decreased in DBD-ARKO males, but overall, the diet did not exaggerate the phenotypic differences between DBD-ARKO and WT males. On the high-fat diet, both WT and DBD-ARKO males showed increased subcutaneous and visceral fat, increased voluntary physical activity, and decreased food intake, the last most likely because the food was energy dense (13) . The high-fat diet also resulted in a switch in oxidation substrate toward fat and elevated serum cholesterol levels in both genotypes; however, there was no increase in glucose, insulin, or triglyceride levels. REE and leptin levels, which were already elevated in DBD-ARKO mice on chow diet, were upregulated by the high-fat diet in WT but not in DBD-ARKO. These data suggest the pathways through which androgens and high-fat diet increase leptin and REE converge, so that there is no additive effect of high-fat diet on these parameters in DBD-ARKO males. However, we cannot rule out the possibility that other components in the diet may be having an effect on phenotype, which is a limitation of the study, as the chow and high-fat diets were not controlled for vitamins, minerals, protein, carbohydrate, or fiber.
A number of genes involved in lipid metabolism are abnormally expressed in DBD-ARKO muscle and fat, indicating either direct or indirect regulation by the AR. Processes regulated include lipid synthesis, quantity of fatty acid and triacylglycerol, and fatty acid transport and lipolysis. We confirmed by qPCR that expression of Aebp1 (transcriptional repressor of the aP2 involved in binding and transport of lipids in adipocytes) is increased in DBD-ARKO muscle, whereas expression of Cbr2 (involved in the reduction of carbonyl compounds), Ucp3 (uncouples proton translocation from ATP synthesis), and Vldlr (involved in the delivery of fatty acids to peripheral tissue) are decreased. Conversely, Aebp1 expression is decreased in fat of DBD-ARKO males, whereas Ucp3 expression is increased. This demonstrates the regulatory cross-talk between fat and muscle and is consistent with the increase in fat mass and decrease in muscle mass in our model. These changes suggest that, in muscle, androgens normally promote fatty acid oxidation and reduce production of reactive oxygen species via Ucp3 (10) and enhance lipid transport into muscle (56) , leading to a reduction in lipid accumulation in fat. In our DBD-ARKO males, although Vldlr is downregulated in muscle, circulating triglyceride levels are unchanged, suggesting that there is increased triglyceride storage in fat tissue. Altered gene expression associated with increased adiposity, including Lep and Lpl, which are elevated on microarray analysis in fat, could not be confirmed by qPCR. This is despite circulating leptin levels being elevated. The expression of Ppar␣, which regulates fatty acid oxidation and energy homeostasis, is increased in DBD-ARKO adipose tissue but normal in muscle, and Ppar␥, which regulates insulin sensitivity and lipogenesis, is normal in DBD-ARKO fat and muscle. In contrast, the Kato group found that Ppar␥ expression is decreased in both white and brown adipose tissue in their AR-null males (14) , whereas the Chang group reported that Ppar␥ expression is increased in white adipose tissue in ARKO males and that Ppar␣ is decreased in skeletal muscle and liver (31) . Our data, generated on a controlled genetic background, suggest the DBD-AR activity does not regulate Ppar␥ expression in either muscle or fat and that the AR normally suppresses Ppar␣ in fat. CREB can stimulate Atf3 expression, which represses Adipoq and Glut4 expression and promotes insulin resistance in obesity (46) . Although phosphorylated CREB protein levels are elevated in fat in our DBD-ARKO males, Glut4 mRNA levels are increased and there is no difference in Atf3 or Adipoq expression on microarray analysis, suggesting that factors other than CREB are also involved in insulin resistance. While many mitogens and other upstream effectors signal through ERK, CREB, and Akt, AR-null ARKO mice are deficient in ERK and PI 3-kinase signaling in some tissues (9, 24, 32) ; but baseline ERK and Akt phosphorylation in our model is normal. While the elevated CREB phosphorylation was surprising, it remains to be determined whether this is due to increased signaling through nongenomic AR pathways in fat.
The major target tissues mediating the metabolic activity of androgens are still not clear, with the three main sites being fat, muscle, and the CNS. An adipose tissue-specific ARKO model (C57BL/6 background) was described by the Chang group that has hyperleptinemia but normal body weight and no increased adiposity (59) . Furthermore, these mice develop hypotriglyceridemia and hypocholesterolemia, suggesting a beneficial role for high leptin levels. Muscle-specific ARKO male mice (mixed C57BL/6 and CD-1 background) also have a surprising decrease in intra-abdominal fat mass (45), suggested to be due to an increase in slow-twitch muscle fiber number, leading to improved insulin action and increased fat oxidation (45) . CNSspecific ARKO (mixed C57BL/6 and 129SvEv background) show growth retardation associated with decreased serum IGF-I levels but no difference in fat or muscle mass (47) . It is difficult to reconcile these tissue-specific knockout results with the data from global AR-null mice, particularly as most studies used mixed genetic backgrounds. Therefore, only the generation and characterization of global, adipose tissue-specific, muscle-specific, and CNS-specific ARKO mice on a homogeneous genetic background will delineate the relative contribution of androgen action in fat and muscle vs. other central and systemic actions on fat mass and metabolism.
In conclusion, our study highlights the importance of genetic background on phenotypic differences between knockout models. This study shows that androgens acting via the DNA binding-dependent actions of the AR regulate fat mass and metabolism in males and that the increased adiposity seen in DBD-ARKO male mice is associated with decreased voluntary physical activity, most likely through AR actions in the CNS, hyperleptinemia, and hyperadiponectinemia and not associated with insulin resistance, hyperphagia, or decreased REE.
